Li Zhang

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

Caicun Zhou, Yi‐Long Wu, Gongyan Chen et al. · The Lancet Oncology · 2011 · 4.1K citations

Medicine, Oncology, Pharmacology +10

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Tony Mok, Yi‐Long Wu, Iveta Kudaba et al. · The Lancet · 2019 · 3.3K citations · Full text

Medicine, Oncology, Pharmacology +15

Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial

Yuankai Shi, Li Zhang, Xiaoqing Liu et al. · The Lancet Oncology · 2013 · 423 citations

Medicine, Oncology, Pharmacology +6

Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial

Roy S. Herbst, Yan Sun, Wilfried Eberhardt et al. · The Lancet Oncology · 2010 · 419 citations · Full text

Medicine, Oncology, Pharmacology +9

Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11)

Yunpeng Yang, Zhehai Wang, Jian Fang et al. · Journal of Thoracic Oncology · 2020 · 396 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17